MT-601 (Neldaleucel)

March 18, 2026 — Marker Therapeutics (Nasdaq: MRKR) reported year-end 2025 corporate and financial results and provided pipeline updates for its multi-antigen recognizing T-cell (MAR‑T) programs.

In the Phase 1 APOLLO trial of MT‑601 in relapsed lymphoma (post–anti‑CD19 CAR‑T or CAR‑T ineligible), an August 2025 update (also presented at ASH 2025) showed a 66% objective response rate (8/12) in relapsed non‑Hodgkin lymphoma with 50% complete responses and response durability of 3–24 months. In Hodgkin lymphoma, ORR was 78% (7/9). Safety was favorable across 100–400×10^6 cells, with no dose-limiting toxicities and no ICANS; dose expansion is enrolling anti‑CD19 CAR‑relapsed DLBCL at 400×10^6 cells. Additional APOLLO data and FDA feedback are expected in Q2 2026.

For pancreatic cancer, Marker cited a January 2026 Nature Medicine publication (Baylor College of Medicine) reporting favorable safety and up to 84.6% disease control when multi-antigen T cells were combined with frontline chemotherapy; Marker plans to start a company-sponsored pancreatic program in Q2 2026.

Business updates included a cGMP manufacturing collaboration with Cellipont (tech transfer expected Q2 2026) and a board appointment (Kathryn Penkus Corzo).

Financially, cash/cash equivalents/restricted cash were $17.0M at Dec. 31, 2025, with runway projected through Q4 2026; 2025 net loss was $12.2M (vs. $10.7M in 2024), with R&D $11.8M and G&A $4.2M.